阿尔茨海默症从对症状治疗进入减缓疾病进展阶段，创新机制药物相较传统药物更具竞争优势，新药研发突破大幅提升市场空间，当年上市药物定价高，市场对创新药品激励充分。阿尔茨海默病（AD）的检测技术已形成“生物标志物+影像+认知评估”的多模态体系，核心是通过量化病理改变、观察脑结构/功能异常、评估认知损伤，实现早期筛查、诊断与病情监测。主流检测方式生物标志物直接反映AD的核心病理机制（淀粉样蛋白沉积、tau...
Source Link阿尔茨海默症从对症状治疗进入减缓疾病进展阶段，创新机制药物相较传统药物更具竞争优势，新药研发突破大幅提升市场空间，当年上市药物定价高，市场对创新药品激励充分。阿尔茨海默病（AD）的检测技术已形成“生物标志物+影像+认知评估”的多模态体系，核心是通过量化病理改变、观察脑结构/功能异常、评估认知损伤，实现早期筛查、诊断与病情监测。主流检测方式生物标志物直接反映AD的核心病理机制（淀粉样蛋白沉积、tau...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.